Navigation Links
Martek Announces Fourth Quarter and FY 2007 Financial Results
Date:12/12/2007

disclosed by the Company, the conclusions of these experts include a

recommendation for pregnant and lactating women to consume at least

200 mg of DHA per day.

Management Outlook

For the first quarter of fiscal 2008, Martek expects total revenues to be between $79 million and $83 million, which include projected non-infant formula nutritional revenue of between $6.2 million and $7.6 million. First quarter gross margin is expected to be between 39% and 39.5%. Net income is projected to be between $6.8 million and $7.5 million, and diluted earnings per share are projected to be between $0.21 and $0.23.

For fiscal 2008, the Company expects growth in both revenues and profitability as compared with fiscal 2007. Martek expects to grow its core infant formula business and expand its penetration into the pregnancy and nursing, nutritional supplements and food and beverage markets. Although the Company expects such growth, Martek is likely to experience quarter-to-quarter fluctuations in both infant formula and non-infant formula nutritional revenues due primarily to variability in customer ordering patterns and the timing of product launches.

Reconciliation of GAAP to Non-GAAP Net Income Measure

The Company makes reference in this release to non-GAAP presentations of net income and earnings per share that exclude the tax benefit from reversal of deferred tax asset valuation allowance and restructuring charge. We are providing this information to assist investors in comparing the results of the current period to those in the prior year periods when the non-recurring items were not present. We caution investors, however, that these non-GAAP results should only be considered in addition to results that are reported under current GAAP and should not be considered as a substitute for results that are presented under GAAP. Following is a schedule showing the reconciliation of net income reported under GAAP to the
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Martek to Announce Third Quarter 2007 Results on September 5, 2007
2. Martek to Present at Upcoming UBS Conference
3. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
7. Martek to Present at Upcoming ThinkEquity Partners Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... West Chester, OH (PRWEB) November 25, 2014 ... International Holdings, has joined the Graphel Carbon Products team ... experience in sales, marketing, and customer service for the ... to add Miles to our team,” stated Dave Trinkley, ... Products. “His wide range of experience in the ...
(Date:11/26/2014)... 2014 Bio-Techne Corporation (NASDAQ: TECH ... Gavin to serve in a newly created position ... Mr. Gavin will be responsible for managing the operations ... ProteinSimple business acquired in July 2014 and the recently ... California -based ProteinSimple develops and commercializes proprietary systems ...
(Date:11/24/2014)...  Last week, Representatives Gus Bilirakis ... a bold bipartisan step on behalf of patients ... Original co-sponsors of the legislation include Representatives McCaul ... drug makers and innovators to "repurpose" major market ... which opens the door to the development of ...
(Date:11/24/2014)... Baltimore, MD (PRWEB) November 24, 2014 ... recruiting underrepresented patient populations into clinical trials at ... Maryland. , “Continental was created with the ... trials play a fundamental role in medical advances," ... the Tuskegee syphilis experiment to the immortal cell ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... 14 Quest Diagnostics,Incorporated (NYSE: DGX ), ... services, announced that it is scheduled to speak,at ... Care Conference on,Tuesday, March 18, 2008, at the ... is scheduled to begin at,8:45 a.m. Eastern Time., ...
... a medical device company focused on developing products for,minimally ... O,Boyle, Executive Vice President and Chief Financial Officer,is scheduled ... Conference at the Loews Miami Beach Hotel in Miami ... ET., A live Web cast of the presentation ...
... Bionovo, Inc.,(Nasdaq: BNVI ) announced today the ... Directors. Mr. Drapeau has extensive financial,management experience with ... quite excited to have access to Lou,s expertise," ... is particularly well versed,in the unique financial scenarios ...
Cached Biology Technology:Quest Diagnostics to Speak at Cowen and Company 28th Annual Health Care Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 3Louis Drapeau Joins Bionovo's Board of Directors 2Louis Drapeau Joins Bionovo's Board of Directors 3
(Date:11/3/2014)... that low birth weight and preterm birth are linked ... adulthood. Findings published in the American College of Rheumatology ... that low birth weight and pre-term babies were not ... as adults. , According to the ACR, 27 ... with clinical OA. Symptoms of OA range from mild ...
(Date:11/2/2014)... of a bold quest to rid the world entirely ... announced an award of US$156 million to PATH to ... new vaccines that will interrupt the cycle of malaria ... agenda. Such vaccines would ensure that parasite reintroduction is ... bed net." , This approach to developing malaria ...
(Date:11/2/2014)... into a bar and bump into a biologist . . ... some late-night nerd sketch, researchers have taken this premise and ... namely, finding meaning in the rising oceans of genomic data. ... mutations that genome-wide studies are publishing at a dizzying rate. ... the signal from the noise (and there is no shortage ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... funded by the National Institute of Allergy and Infectious ... (NIH), have engineered a powerful inhibitor of anthrax toxin ... "This novel approach to the design of anthrax antitoxin ... it may have in anthrax treatment, but also because ...
... have discovered the gene responsible for a type of ... coordination. , This is the first neurodegenerative disease shown ... spectrin which plays an important role in the maintaining ... historical implications as well--the gene was identified in an ...
... study of the travels of the malaria parasite Plasmodium ... Paris found the parasites developing in an unexpected place: ... lymph nodes almost certainly has implications for the mammalian ... Institute (HHMI) international research scholar who led the study. ...
Cached Biology News:Scientists design potent anthrax toxin inhibitor 2Scientists design potent anthrax toxin inhibitor 3U of MN researchers identify ataxia gene 2Malaria parasites develop in lymph nodes 2Malaria parasites develop in lymph nodes 3
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: